Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Eli Lilly is requesting medical records from patients who took compounded versions of tirzepatide amid safety concerns and ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

For people who pay out of pocket, Lilly recently introduced vials of its drug Zepbound that cost as little as 399 dollars a month. To compete, Novo Nordisk ramped up its rebating -- average Wegovy ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.81% and ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.